SDZ:SIXSandoz Group Ltd Analysis

Sandoz (SDZ.SW) is trading at CHF 62.9, just above the calculated support of CHF 62.32 but below its 20‑day (CHF 65.5) and 50‑day (CHF 64.3) moving averages, suggesting short‑term pressure. The RSI sits at 41, indicating neutral momentum, while the MACD is bearish with the line below the signal, reinforcing a cautious near‑term outlook. Volatility is elevated at 28% over the past 30 days, yet the beta of roughly 0.2 points to limited systematic risk. The stock’s trailing P/E of 38.4 is well above the industry average of 27.2, and the DCF‑derived fair value of CHF 35.2 implies the market is pricing in a substantial premium. Despite this, the company posted 10.7% revenue growth, a forward EPS of 3.73 and a forward P/E of 16.9, highlighting strong growth momentum. Dividend sustainability looks solid with a 1.27% yield, a modest 35% payout ratio and robust free cash flow. Recent material news – a 19% post‑earnings rally, a strategic biosimilar partnership with Samsung Bioepis, and an analyst upgrade to “Buy” – provide fresh upside catalysts. However, the “Extreme Greed” reading on the Fear & Greed Index suggests market sentiment may be overly optimistic. In sum, the stock appears overvalued on valuation metrics, but growth prospects and dividend safety temper the downside risk.